MedPath

Pain Control in Children and Adolescent After Thoracic Surgery: The Effect of Gabapentin

Phase 4
Completed
Conditions
Surgery, Thoracic
Pain, Postoperative
Interventions
Drug: Placebo
Registration Number
NCT03393702
Lead Sponsor
National Institute for Tuberculosis and Lung Diseases, Poland
Brief Summary

The study is performed in patients aged 5-18 years after thoracic surgery. The primary aim of this trial is to determine whether the use of gabapentin as a component of multimodal analgesic regiments reduces pain scores following thoracic surgery in pediatric patients. The secondary objective of the trial are to evaluate whether the use of gabapentin reduces postoperative anxiety scores and consumption of ropivacaine with fentanyl, decreases side-effects, and improves patient satisfaction.

Detailed Description

The subjects are randomized to the Gabapentin or Placebo group. All patients receive preoperative gabapentin (15 mg/kg, treatment) or placebo, respectively and after surgery either gabapentin (7,5 mg/kg, treatment) or placebo 2 times per day for 3 days, respectively.

Patients are subjected to the same anaesthesia protocol. Postoperative analgesia are achieved with either continuous ropivacaine 0.2%/fentanyl 5.0 μg/ml infusion through a thoracic epidural catheter (N=40; Gabapentin n=20, Placebo n=20), or intravenous infusion of morphine (N=40; Gabapentin n=20, Placebo n=20). All patients receive acetaminophen and non-steroidal anti-inflammatory drugs, and metamizol as a "rescue drug"

The intravenous infusion of morphine grup was expanded on the basis of the bioethics commission's decision KB-125/2019 (N=64; Gabapentin n=32, Placebo n=32).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
104
Inclusion Criteria
  • 5 - 18 years of age;
  • surgery: lateral thoracotomy or Ravitch procedure;
  • ASA 1-3;
  • postoperative analgesia: thoracic epidural analgesia or intravenous infusion of morphine.
Exclusion Criteria
  • allergy or sensitivity to gabapentin;
  • history of chronic pain or daily analgesic use;
  • diagnosed with psychiatric disorders;
  • treated oncologically;
  • with impaired verbal communication;
  • the lack of postoperative chest drainage.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo ControlPlacebo1. Single dose preoperative placebo control. 2. After surgery placebo 2 times per day for 3 days.
GabapentinGabapentin1. Single dose preoperative gabapentin. 2. After surgery gabapentin 2 times per day for 3 days.
Primary Outcome Measures
NameTimeMethod
Pain intensity scores at rest (FLACC for patients <7 y.o., NRS for patients >7 y.o.)postoperative day: 0-3
Pain intensity scores during deep breathing (FLACC for patients <7 y.o., NRS for patients >7 y.o.)postoperative day: 0-3
Pain intensity scores during coughing (FLACC for patients <7 y.o., NRS for patients >7 y.o.)postoperative day: 0-3
Secondary Outcome Measures
NameTimeMethod
Total ropivacaine/fentanyl consumption.postoperative day: 0-3
Side Effect Occurrencefirst 3 days after surgery

Incidence and severity of nausea, vomiting, pruritis, sedation, dizziness, urinary retention, complication in relation to administering of the drugs to epidural space.

Total morphine consumption.postoperative day: 0-3
Patient satisfaction.first 3 days after surgery

Responses can range from 0 (very dissatisfied) to 10 (very satisfied).

Anxiety intensity scores.before surgery, postoperative day 3

Patients rate their anxiety using State-Trait Anxiety Inventory.

The number of doses of metamizol as a "rescue drug"postoperative day: 0-3

Trial Locations

Locations (1)

Institute for Tuberculosis and Lung Diseases, Pediatric Division

🇵🇱

Rabka-Zdrój, Małopolska, Poland

© Copyright 2025. All Rights Reserved by MedPath